M.D. Anderson Cancer Center: Carcinoma, Ovarian Epithelial trials

The registry lists 26 Carcinoma, Ovarian Epithelial studies with M.D. Anderson Cancer Center as lead sponsor. 0 are open to participants now and 6 have results posted.

Early Phase 1 2Phase 1 9Phase 2 7No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT04019288Phase 1/2Results posted
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal AdenocarcinomaTerminatedNCT03610490Phase 2Results posted
• First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT01097746Phase 2Results posted
• Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer PatientsTerminatedNCT00583622Phase 2Results posted
• Gleevec Study for Patients With Ovarian CancerCompletedNCT00510653Phase 2Results posted
• Chemoimmunotherapy Study for Patients With Epithelial Ovarian CancerCompletedNCT00501644Phase 2Results posted
• A Phase I Study of SOR-C13 in Patients With Advanced Solid TumorsCompletedNCT03784677Phase 1
• TAK-659 and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT03756818Phase 1
• Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisCompletedNCT03508570Phase 1
• Mesenchymal Stem Cells (MSC) for Ovarian CancerCompletedNCT02530047Phase 1
• Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02316834Early Phase 1
• Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01504126Early Phase 1
• Juice Plus+ and Juice Plus+ Complete in Ovarian CancerActive, not recruitingNCT01439659Phase 2
• M. D. Anderson Symptom Inventory - Ovarian CancerCompletedNCT01037751
• Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal CancerTerminatedNCT00897806
• Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)CompletedNCT00829959
• Cost Utility Analysis in Recurrent Ovarian CancerWithdrawnNCT00813254
• Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian CancerCompletedNCT00529022Phase 1
• Quality of Life Associated With a Low-Risk Screening Program for Ovarian CancerStatus unknownNCT00511641
• Chemotherapy-Related Toxicities In Ovarian Cancer PatientsCompletedNCT00508378
• Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube CancerStatus unknownNCT00499512
• Ovarian Cancer Patient Questionnaire on Genetic TestingCompletedNCT00486707
• Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian CancerCompletedNCT00431054Phase 1
• Elizabeth Registry for Low Grade Ovarian CancerCompletedNCT00345709
• Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian CancerTerminatedNCT00102622Phase 1
• PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube CancerCompletedNCT00059618Phase 1